Colorectal Disorders

Mesalamine Formulation Switch Linked to Acute Renal Failure in UC Patient

By October 17, 2017

The 35-year-old male from Hawaii maintained clinical remission with Lialda, a once-daily formulation of mesalamine, and infliximab.

Same-Day vs. Split Dose Bowel Prep for Colonoscopy Compared

By October 16, 2017

Results showed that adenoma detection rate (ADR) did not differ between groups. Additionally willingness to repeat and tolerability did not differ.

New Therapeutic Drug Monitoring Test for Ustekinumab Announced

By October 16, 2017

By measuring drug and antibody concentrations physicians can adapt treatment strategies and guide patients toward more personalized medicine.

Noninvasive Test Monitors Healing Status in Crohn's Disease Patients

By October 16, 2017

The PROMETHEUS Monitr Crohn's Disease test can be used as an adjunct to endoscopy or by itself between endoscopies.

Impact of Early Azathioprine Use on Crohn's Disease Progression Evaluated

October 02, 2017

Prior bowel resection, smoking, and low hemoglobin tied to Crohn's-related surgery

Hair Regrowth in Alopecia Patients After Fecal Transplant for Recurrent CDI

By September 22, 2017

These 2 cases suggests that fecal transplants can have a profound immunological response not only limited to intestinal effects, say the authros.

Does Prenatal Biologic Therapy for IBD Affect Infant Vaccine Response?

By September 18, 2017

In addition, the researchers assayed umbilical cord blood samples from 33 infants to assess the concentration of biologic agents.

Higher Incidence of GI Symptoms in Female IBS Patients on Clopidogrel

By September 11, 2017

The results showed a higher proportion of patients with GI symptoms on clopidogrel (68%) compared to controls (60%, P=0.0011) that were Females (70% vs. 60%, P=0.0003) not Males (61 vs. 60%; P=0.8312).

Pediatric Ulcerative Colitis Tx Granted Orphan Drug Designation

By September 08, 2017

Early Phase 1 data has indicated that the treatment drug can be more efficacious than mesalamine/5-ASA treatments alone.

FDA Reveals Stem Cell Policy Plans Amid Clinic Crackdowns

By August 28, 2017

An FDA inspection of the clinic found that adipose tissue was being processed into stromal vascular fraction (stem cells derived from body fat) which was then administered intravenously or directly into the spinal cord of patients.

Biosimilar Cyltezo Gets FDA Approval for Multiple Indications

By August 28, 2017

This marks the second approval of a biosimilar for adalimumab.

Model May Predict Colectomy Likelihood at First Colitis Episode

August 21, 2017

At index admission, 11% of patients underwent colectomy, and 26% had one over a median follow-up of 56 months.

AGA: Recommendations for Monitoring Drug Therapy in IBD

By August 14, 2017

To optimize drug concentration and improve outcomes, therapeutic drug monitoring is used to check the trough concentration and evaluate for the presence of anti-drug antibodies.

Mytesi Granted Orphan Drug Designation for Short Bowel Syndrome

By August 07, 2017

Clinical studies of Mytesi have shown that the most common adverse reactions were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough, and flatulence (3.1%).

Biosimilar Renflexis Now Available

July 24, 2017

Infliximab products work by neutralizing the biological activity of TNF-alpha by binding with high affinity to the soluble and transmembrane forms of TNF-alpha and inhibiting the binding of TNF-alpha with its receptors.

Diagnosing and Treating Exocrine Pancreatic Insufficiency

By July 17, 2017

A recent opinion piece by Struyvenberg et al. aims to address the existing myths, remove the current confusion, and function as a practical guide to the diagnosis and treatment of EPI.

How Common Is EPI in Patients with Chronic Abdominal Pain, Diarrhea?

By July 17, 2017

Overall, pancreatic exocrine insufficiency was identified in 10 patients (4.6%; 95% CI 2.2-8.3%) with five patients having severe pancreatic exocrine insufficiency (2.3%; 95% CI 0.8-5.3%).

Value of Enhanced Recovery Protocol in Colon, Rectal Sx

July 11, 2017

Based on one retrospective review of 8 years of compliance, the strongest predictors of shorter length of stay were identified as no nasogastric tube, early mobilization, early oral nutrition, early removal of epidural and urinary catheter, and nonopioid analgesia.

No Signs of Abuse Potential with Eluxadoline in IBS-D

July 10, 2017

The researchers found that there was no significant difference between the groups in terms of adverse events potentially related to abuse (2.8, 2.7, and 4.3%, respectively, for those given placebo, eluxadoline 75mg, or eluxadoline 100mg)

Task Force Issues New CRC Screening Recommendations

By June 21, 2017

Individuals with a family history of CRC in a first-degree relative diagnosed before age 60 should undergo colonoscopy every 5 years beginning at age 40 or 10 years before the age at which their relative was diagnosed.

Extent of Microbial Repopulation Examined Following Fecal Transplant

June 19, 2017

In 2 of the patients, some donor microbe strains persisted as long as 2 years after a transplant. In 5 others, donor strains persisted for 3 to 6 months, according to the University of Alabama at Birmingham researchers.

Uceris Evaluated in Mesalamine-Refractory Ulcerative Colitis

By May 18, 2017

At Week 8, combined clinical and endoscopic remission was obtained in 13.0% of budesonide MMX patients vs. 7.5% of placebo patients.

Tenapanor Achieves Primary Endpoint in IBS-C Trial

By May 12, 2017

Results showed that the endpoint was met with 27% in the tenapanor arm compared to 18.7% in the placebo arm (P=0.02) having at least 30% reduction in abdominal pain and an increase of 1 or more complete spontaneous bowel movements.

Managing Abdominal Pain in IBD: A Review

By May 09, 2017

Researchers analyzed 13 intervention studies which evaluated various psychological, dietary, and drug interventions.

Tofacitinib Effective for Moderate-to-Severe Ulcerative Colitis

May 04, 2017

A total of 18.5% patients taking tofacitinib experienced a remission of their condition in 8 weeks compared to just 8.2% of patients receiving placebo.

New Therapeutic Option for Crohn's Disease Looks Promising

May 03, 2017

Five of seven patients from pilot study were in deep remission at six-month follow-up

Biosimilar Renflexis Gets FDA Approval

By April 21, 2017

A biosimilar product must demonstrate no clinically meaningful differences in safety or efficacy from the reference product.

CDC Analyze Hospitalization Rates for Crohn's Disease in Last Decade

April 14, 2017

Stable trends for a first-listed Crohn's disease diagnosis from 2003 to 2013 suggest that the previous annual increase has not continued.

Does IBD Impact Response to Booster Pertussis Dose?

By April 12, 2017

The data showed no difference in the rates of adequate vaccine response between the 4 study groups (P=0.11). Patients with IBD taking immunosuppressive therapy did not differ from those not taking immunosuppressive therapy (90.6% vs. 88.2%; P=0.37).

Risankizumab for Moderate-to-Severe Crohn's Disease

By April 12, 2017

Feagan, BG et al. "Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study"